» Articles » PMID: 33628677

Intracranial Grade II Meningioma Oligometastatic to the Cervical Spine

Overview
Journal Cureus
Date 2021 Feb 25
PMID 33628677
Authors
Affiliations
Soon will be listed here.
Abstract

For intracranial meningiomas that metastasize extracranially, an oligometastatic state exists that is intermediate between incurable, widely metastatic disease and non-metastatic curable disease. Similar to oligometastatic cancer, aggressive local treatment of meningioma oligometastases is warranted, as it may be curable. We present a patient with multiply recurrent intracranial meningiomas over 19 years, with a transformation from grade I to grade II histology, with oligometastatic disease to the C5 vertebral body. Three years following definitive spinal stereotactic radiosurgery, she remains without evidence of other metastatic diseases. Our case highlights the oncologic concept that metastatic meningioma need not be widely disseminated and provides the clinical rationale for aggressive local treatment of an oligometastatic meningioma.

References
1.
Palma D, Salama J, Lo S, Senan S, Treasure T, Govindan R . The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014; 11(9):549-57. DOI: 10.1038/nrclinonc.2014.96. View

2.
Vakil H, Tran L, Lewis G, Cykowski M, Butler E, Teh B . Biopsy proven metastatic meningioma: A case report and review of the literature. Rep Pract Oncol Radiother. 2019; 24(6):528-532. PMC: 6732750. DOI: 10.1016/j.rpor.2019.08.002. View

3.
Paix A, Waissi W, Antoni D, Adeduntan R, Noel G . Visceral and bone metastases of a WHO grade 2 meningioma: A case report and review of the literature. Cancer Radiother. 2017; 21(1):55-59. DOI: 10.1016/j.canrad.2016.09.012. View

4.
Otake S, Goto T . Stereotactic Radiotherapy for Oligometastasis. Cancers (Basel). 2019; 11(2). PMC: 6407034. DOI: 10.3390/cancers11020133. View

5.
Ostrom Q, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol. 2019; 21(Suppl 5):v1-v100. PMC: 6823730. DOI: 10.1093/neuonc/noz150. View